Compare NKX & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKX | OABI |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 696.4M |
| IPO Year | 2002 | 2021 |
| Metric | NKX | OABI |
|---|---|---|
| Price | $10.85 | $4.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 412.1K | ★ 1.3M |
| Earning Date | 01-01-0001 | 10-30-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,666,000.00 |
| Revenue This Year | N/A | $87.73 |
| Revenue Next Year | N/A | $25.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.30 | $1.32 |
| 52 Week High | $13.20 | $5.43 |
| Indicator | NKX | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 52.65 |
| Support Level | $10.30 | $1.93 |
| Resistance Level | $12.59 | $5.06 |
| Average True Range (ATR) | 0.21 | 0.35 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 54.50 | 55.60 |
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.